← Back to Search

Intravenous Ketamine for Major Depressive Disorder

Phase 3
Waitlist Available
Led By Pierre Blier, MD, PhD
Research Sponsored by University of Ottawa
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3-4 weeks
Awards & highlights

Study Summary

This trial will compare the effects of electroconvulsive therapy (ECT) and ketamine in people with depression who haven't responded to other treatments.

Eligible Conditions
  • Depression
  • Major Depressive Disorder
  • Depression, Bipolar Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3-4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3-4 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Montgomery-Asberg Depression Rating Scale

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Intravenous KetamineExperimental Treatment1 Intervention
Group II: Electroconvulsive TherapyActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ketamine
FDA approved

Find a Location

Who is running the clinical trial?

Ontario Shores Centre for Mental Health SciencesOTHER
12 Previous Clinical Trials
1,898 Total Patients Enrolled
Queen's UniversityOTHER
369 Previous Clinical Trials
121,310 Total Patients Enrolled
University Health Network, TorontoOTHER
1,483 Previous Clinical Trials
486,282 Total Patients Enrolled
~48 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top